In a report released yesterday, Michael Ryskin from Bank of America Securities reiterated a Buy rating on Labcorp Holdings (LH – Research Report), with a price target of $282.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Michael Ryskin has given his Buy rating due to a combination of factors that highlight Labcorp Holdings’ strong performance and growth potential. The company reported solid fourth-quarter results, with sales and adjusted earnings per share exceeding expectations. For fiscal year 2025, Labcorp has provided a sales guidance that is ahead of both Bank of America and Street estimates, indicating a positive outlook.
Additionally, Labcorp expects to see margin expansion in the second half of 2025, driven by volume growth in its core laboratory diagnostics business. The company is also focusing on mergers and acquisitions as a key strategy for capital deployment, strengthening its position with a solid pipeline of potential acquisitions. With a disciplined approach to acquisitions and a strong financial position, Labcorp is poised for continued growth, further justifying the Buy rating.
Ryskin covers the Healthcare sector, focusing on stocks such as Agilent, Bruker, and Charles River Labs. According to TipRanks, Ryskin has an average return of 1.9% and a 50.50% success rate on recommended stocks.
In another report released yesterday, Jefferies also reiterated a Buy rating on the stock with a $290.00 price target.